You searched for "Lucentis"
Corporate M&A pace gathers momentum
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
Uveitis in the elderly
This study from Turkey evaluated the causes and clinical characteristics of uveitis in elderly patients. Data from 90 eyes of 68 patients aged 60 years and older were reviewed. Anterior uveitis was present in 75% (33% of these had keratouveitis),...
Sarcoid uveitis and its systemic associations
This retrospective cross-sectional study examined systemic associations of sarcoid uveitis and association with uveitis clinical phenotype and ethnicity. Three hundred and sixty-two subjects with either definite or presumed sarcoid uveitis were identified and included in the study. Any subject with...
Uveitis in HIV infected persons
Before the advent of highly active antiretroviral therapy (HAART), uveitis, in particular cytomegalovirus (CMV) retinitis, was the most common cause of visual loss in patients with AIDS. HAART has altered the cause of ocular disease in HIV infected individuals by...A paradigm shift in the way we approach cataract surgery
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...NICE drugs: an update on what’s good to go
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...
Systemic anti-inflammatory versus fluocinolone acetonide intraocular implant
In the Multicenter Uveitis Steroid Treatment (MUST) trial, 255 patients with intermediate uveitis, posterior uveitis or panuveitis were randomised to either fluocinolone acetonide intraocular implant or systemic corticosteroid therapy which was supplemented with immunosuppression if required. Patients were followed up...
